Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case

Saved in:

Bibliographic Details
Main Authors:	Huiyun Lv, Wei Liu, Yang Zhang, Chen Song
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Asian Journal of Surgery
Subjects:	Pancreatic metastasis Tyrosine kinase inhibitors (TKIs) Anti-HER2 therapy Breast cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958424017664
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-09-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

Ibrutinib-associated osteonecrosis of the jaw
by: Annu Singh, et al.
Published: (2024-03-01)

A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified  Lung Squamous Cell Carcinoma and Literature Review
by: Yalan LIU, et al.
Published: (2024-11-01)

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
by: Liu Y, et al.
Published: (2025-01-01)

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
by: Yukihiro Umeda, et al.
Published: (2025-01-01)

Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma
by: Dan Liu, et al.
Published: (2025-01-01)

Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature
by: Neerja Saraswat, et al.
Published: (2024-01-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01)

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015
by: A. M. Popov, et al.
Published: (2016-01-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based influenza model
by: Si Chen, et al.
Published: (2025-01-01)

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age
by: Mototsugu Oya, et al.
Published: (2025-01-01)

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study
by: Fazeel Zubair Ahmed, et al.
Published: (2025-01-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
by: Sofija Kozarac, et al.
Published: (2025-01-01)

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
by: Piyada Sitthideatphaiboon, et al.
Published: (2025-01-01)

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
by: Maria Elena Lacruz, et al.
Published: (2025-02-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
by: Nada Alghamdi, et al.
Published: (2025-01-01)

Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach
by: Xingping Zhang, et al.
Published: (2025-01-01)

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
by: Sangita A. Vanik, et al.
Published: (2023-07-01)

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
by: Jialin Qian, et al.
Published: (2025-03-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy
by: Sara Cherradi, et al.
Published: (2025-01-01)

Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
by: Swagata Sinha, et al.
Published: (2024-12-01)

Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis
by: Zhonghua Zhao, et al.
Published: (2025-01-01)